# Exscientia

the Centaur Chemist platform; in 2020 it became the first company to advance an AI-designed drug (DSP-1181) into human clinical trials, and since November 2024 it has operated as part of Recursion.

Source: https://en.bioecon.ru/companies/exscientia/
Updated: 2026-06-30

- Country: United Kingdom

## Technologies

- [AI drug design & AlphaFold applications](https://en.bioecon.ru/technology/ai-drug-design-alphafold-applications/)